Is a Certificate of Analysis available
Up to six months, retatrutide users will typically experience a greater average weight loss, occasionally exceeding 15 percent of their initial weight
Unlock your healthiest body yet Promo: $45 first month, $145/month thereafter Access to doctor-prescribed GLP-1s Personal health coaching via video chats and messaging Personalized weight loss plan Insurance concierge to help navigate medication coverage
Timing : Apply at consistent times as directed to maintain steady drug levels
Further inquiries can be directed to the corresponding author
NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
